Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc is a specialty pharmaceutical company focused on developing and commercializing innovative therapies to address unmet medical needs, particularly in pediatric oncology. The company’s lead product, PEDMARK, is an FDA-approved therapy designed to reduce the risk of hearing loss in children receiving cisplatin chemotherapy, a significant advancement in supportive cancer care. Fennec generates revenue primarily through the commercialization of PEDMARK in the United States and through licensing agreements in other territories. Founded in 1996 and headquartered in Durham, North Carolina, Fennec has a history of targeting rare pediatric diseases and has built partnerships with leading cancer centers and advocacy organizations. Candidates should be aware of the company’s commitment to patient-centric solutions and its recent milestones in regulatory approvals and market expansion.

Recent Posts by Fennec Pharmaceuticals

1-4 of 4